Kairos Pharma, LTD. — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Kairos Pharma amended its 2023 Equity Incentive Plan (effective June 29, 2026) establishing a maximum of 6.65 million shares available for future grants of options, RSUs, restricted stock, and performance awards to employees, directors, and consultants. The plan includes an automatic 5% annual share reserve increase on January 1 each year from 2027–2033 (based on prior year outstanding shares), subject to board discretion to reduce or eliminate any given year's increase. No specific grants, counterparties, or dollar amounts are disclosed in this plan document.
Why this rating
Plan authorization is administrative/routine. 6.65M shares at micro-cap $6.9M market value represents material dilution potential; however, no awards granted yet, and equity plans are standard corporate governance. Neutral absent actual grant disclosures.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.